Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.45 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.45 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.45 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.45 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108531 | 0.84 | CES2 (0.61) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL15471929 | 0.82 | ALDH1A1 (0.61) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL24210299 | 0.82 | KEAP1 (0.63) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL1544647 | 0.82 | ALDH1A1 (0.70) | ALDH1A1MAPTKDM4ETAS1R3TAS1R1 | |
| SCHEMBL1639721 | 0.82 | P2RX1 (0.54) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL15471931 | 0.81 | ALDH1A1 (0.44) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL15471930 | 0.81 | ALDH1A1 (0.68) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL22466424 | 0.81 | F2R (0.51) | CES2CES1ALDH1A1MAPTKDM4E | |
| SCHEMBL15471932 | 0.81 | OGG1 (0.50) | CES2ALDH1A1MAPTKDM4EGFER | |
| SCHEMBL5314181 | 0.81 | CES2 (0.57) | CES2CES1MAPTTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| CN-115135152-A | 1, 5-diphenylpyrazolyl-3-oxyalkyl acids and 1-phenyl-5-thienylpyrazolyl-3-oxyalkyl acids and their use for controlling undesired vegetation | 拜耳公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9499503-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2220061-B1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2220061-B1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9102639-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006031348-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-6872720-B2 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. | 2005-03-29 | — | — | US | disclosed |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-27 | — | — | US | disclosed |
| EP-1282623-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-6476030-B1 | Pyrazolo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2002-11-05 | — | — | US | disclosed |
| WO-2001077111-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-10-18 | — | — | WO | disclosed |
| EP-1121361-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | Merck Sharp & Dohme Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023449-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885ALDH1A1 3542/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | CES2 4225/4885CES1 2914/4885ALDH1A1 1990/4885 |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885ALDH1A1 3542/4885 |
| US-20030060467-A1 | Pyrazolo-triazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA4 | CES2 1395/4885CES1 2047/4885ALDH1A1 1121/4885 |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885ALDH1A1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.